Navigation Links
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Date:4/8/2011

t Due to DME) has three study arms.  In the first arm, patients will be treated every month with 2 milligrams (mg) of VEGF Trap-Eye.  In the second arm, patients will be treated with 2mg of VEGF Trap-Eye every two months after a loading phase of monthly injections.  In the third arm, the comparator arm, patients will be treated with macular laser photocoagulation.  The primary endpoint is mean change in visual acuity from baseline as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart, a standard chart used in research to measure visual acuity.  All patients will be followed for three years.  The VISTA-DME study (VEGF Trap-Eye: Investigation of Safety, Treatment effect, and Anatomic outcomes in DME) is expected to begin later in 2011.

About Diabetic Macular Edema (DME)

DME is the most prevalent cause of moderate vision loss in patients with diabetes.  DME is a common complication of Diabetic Retinopathy (DR), a disease affecting the blood vessels of the retina.  Clinically significant DME is a leading cause of blindness in younger adults (under 50).  Clinically significant DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision.  Fluid in the macula can cause severe vision loss or blindness.

According to figures from the World Health Organization, DME is the second leading cause of blindness in Western industrialized countries.  In Europe, about 8% of the population is affected by DME.  Approximately 370,000 Americans currently suffer from clinically significant DME, with 95,000 new cases arising each year.  According to the American Diabetes Association, over 18 million Americans currently suffer from diabetes, and many more are at risk for developing diabetes.  The incidence of diabetes is steadily climbing and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 The ... Growing ageing population and rise in the incidence of ... chronic wounds and in affordability of better quality of ... wound care market. Universal coverage of public health insurance ... would further stimulate demand. Based on the findings of ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... Power plant standards to cut climate-changing carbon emissions ... substantial human health benefits, according to a new ... on the policy options included in the final ... prevent thousands of premature deaths and hospitalizations, and ... every year., In the new study, Health Co-benefits ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... docs determine who would benefit most from chemo after surgery, ... panel of 15 genes may help determine which patients with ... therefore, benefit the most from chemotherapy, a new study shows. ... identify patients with less aggressive forms of the cancer who ...
... 16 As tropical storms,continue to batter the ... Nargis are vulnerable to diseases and other severe ... the foul weather and,malnutrition are creating an increasingly ... conditions urgently need more help to,recover from this ...
... More in 2007, WASHINGTON, May 16 While ... Cancer Institute (NCI) invested,less than 5% of its $4.8 ... updated statistics issued by Lung Cancer Alliance (LCA) today., ... research,programs -- Centers for Disease Control and Prevention (CDC) ...
... SAN DIEGO, May 16 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that on May 8, 2008, two alleged ... Superior Court of the State,of California, County of San ... Directors of CryoCor, CryoCor and Boston Scientific Corporation.,The complaint ...
... for at least a year or two, , , FRIDAY, ... people with type 1 diabetes live insulin-free for at ... longer-term improved metabolic control even after people have to ... glucose monitoring systems, researchers from the University of Miami ...
... The Centers for Disease,Control and Prevention (CDC) and ... have selected LMI for the Partners in Public,Health ... the Division,of the Strategic National Stockpile (DSNS) in ... has worked with LMI,s Health,Systems Management group, supplemented ...
Cached Medicine News:Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: